| |
Count (%)
|
Age (y)
|
PSA (ng/mL)
|
|---|
|
Median
|
Range
|
Median
|
Range
|
|---|
|
Low risk
|
97 (26.2%)
|
64.6
|
48.5–78.3
|
5.74
|
0.2–38.4
|
|
Intermed. risk
|
45 (12.1%)
|
64.9
|
50.6–76.9
|
12.9
|
2.9–83.8
|
|
High risk
|
229 (61.7%)
|
65.5
|
46.7–77.4
|
9.9
|
0.3–113
|
|
T2a–c
|
165 (44.5%)
|
65.1
|
46.7–78.3
|
7.2
|
0.2–45.1
|
|
T3a-b
|
144 (38.8%)
|
65.9
|
54.1–77.4
|
8.7
|
0.3–74.8
|
|
T4
|
62 (16.7%)
|
63.2
|
50.6–76.5
|
15.8
|
2.8–113
|
|
GS ≤ 6
|
73 (19.7%)
|
64.3
|
48.5–77.1
|
5.6
|
0.2–83.8
|
|
GS7
|
69 (18.6%)
|
65.6
|
50.6–78.3
|
8.0
|
2.9–50
|
|
GS8
|
147 (39.6%)
|
66.1
|
46.7–77.4
|
10.5
|
0.3–113
|
|
GS ≥ 9
|
82 (22.1%)
|
64.6
|
51.1–77.1
|
8.8
|
0.3–65.5
|
- PCa prostate cancer, IHC immunohistochemical analysis, TMA tissue microarray, TET1 ten–eleven translocation family member 1, y years, PSA prostate-specific antigen, T tumor stage, GS Gleason score, Intermed. risk intermediate risk
